▲ Ms. Carolyn Britten, Vice President of Early Development Oncology at Amgen, Professor Tae Won Kim, President of Cancer Institute, and Professor Chong Jai Kim, Director of Asan Institute for Life Sciences(front row, sixth, seventh, and eighth from the left), and other participants are gathered for a commemorative photo.

Ms. Carolyn Britten, Vice President of Early Development Oncology at Amgen, along with members of the R&D leadership team, visited Asan Medical Center for a period of two days starting on August 2nd. In May, Asan Medical Center entered into a global network agreement with Amgen known as APoC (Amgen Partners of Choice), with the aim of collaborating on cancer research and advancing novel cancer treatments with renowned hospitals worldwide. Asan Medical Center is the only APoC member in Korea.

This visit was arranged to discuss the acceleration of new drug research and development through the APoC network, as well as to strengthen collaborative efforts between the two institutions. During the visit, the delegation engaged with the leadership of Asan Medical Center, including Professor Chong Jai Kim, Director of the Asan Institute for Life Sciences & CRO, as well as medical professionals in the field of cancer, including those from the Division of Oncology and the Department of Nuclear Medicine. The delegation was provided with an explanation of the accomplishments of Asan Medical Center in cancer treatment and research, as well as insights into the research infrastructure. Furthermore, Amgen presented its achievements in new drug development and outlined its future directions.